Novo Nordisk’s Oral Wegovy Smashes Expectations, but Margin Pressure and Rival Threats Cloud the O
Oral Wegovy nearly doubles Q1 sales, Citi boosts long-term forecast to 50B kr, but competition and pricing headwinds…
Browsing Tag